Biotech is now the deepest pocket of leadership in the entire Nasdaq. Everyone can see biotech is moving, and the why is ...

Sofinnova Investments’ Jim Healy says biotech innovation is thriving but is skeptical about artificial intelligence’s ability ...

Krystal Biotech, Inc. (KRYS) shares soared 3.4% in the last trading session to close at $372.25. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.

Spyre Therapeutics SYRE has given investors a classic biotech dilemma. The pipeline is advancing, the cash balance is large ...

Three mid-cap biotechs have become prime acquisition targets, but only one offers what big pharma is hunting for most.

IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...

The new outfit, called Saturnus Bio, was announced today by Merck KGaA, and will focus on developing medicines for rare ...

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

Ernst & Young's 2026 biotech report shows 13% revenue growth to $232B, but US policy shifts, patent cliffs and uneven ...

Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, ...